New hope for hard-to-treat lymphoma? drug combo enters human testing
NCT ID NCT07279584
First seen Jan 11, 2026 · Last updated May 14, 2026 · Updated 16 times
Summary
This study tests whether adding the drug golidocitinib to standard chemotherapy (GemOx) can shrink tumors in people with a rare blood cancer called peripheral T-cell lymphoma that has returned or not responded to prior treatment. About 31 adults will receive the combination and be monitored for safety and how well the cancer responds. The goal is to control the disease, not to cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERIPHERAL T-CELL LYMPHOMAS (PTCL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.